AbbVie is on the verge of finalizing a significant acquisition, targeting Apogee Therapeutics for nearly $11 billion. This move is part of a broader trend in the biotech industry, where major pharmaceutical companies are actively seeking to expand their drug pipelines.
The deal highlights the growing interest in biotech as firms look to innovate and secure new therapies. As competition intensifies, securing promising biotech firms has become a strategic priority for Big Pharma.
The acquisition, if completed, could position AbbVie favorably within the market, potentially enhancing its portfolio with Apogee's offerings. This development is expected to be closely watched by industry analysts and investors alike.